XANO's Interim Report Q1-Q3 2025

 

XANO's Interim Report for Q1-Q3 2025 is now available, providing a detailed overview of the Group's financial performance and operational developments during the first nine months of the year. 

Access the report by clicking on the image to the right.

XANO 2025-Q3 ENG.jpg

Strong quarter in a challenging market

 

The Group companies’ efforts to adapt their operations, together with margin-enhancing measures, have continued to yield increasing results, and operating profit for the third quarter significantly exceeded that of the comparison period. In addition to improved margins, the sale of a property company contributed to the strong earnings performance and high cash flow for the period.

In terms of sales, continued growth in medical technology, pharmaceuticals, and defence, along with a slight recovery in the can manufacturing industry and the agricultural sector, offset generally lower project volumes. 

Compared with the third quarter of the previous year, turnover increased by just under 7%. The operating profit for the period of SEK 110 million (13) and operating margin of 14.0% (1.7) include a capital gain on the divestment of a property company, but even excluding this, the improvement was significant. Adjusted operating profit was SEK 69 million (27) and adjusted operating margin 8.8% (3.6).  

 

Lennart Persson, President and CEO

Outcome Q1–Q3

Net revenue

2,558

(SEK m)

Operating profit

270

(SEK m)

Operating margin

10.6

(%)

Profit margin

8.3

(%)

Net profit

168

(SEK m)

Earnings per share

2.83

(SEK)